Pharmacoeconomic research of using aflibercept in patients with the wet age-related macular degeneration by S. V. Nedogoda, A. S. Salasyuk, E. V. Bobykin, I. N. Barykina, V. O. Smirnova, E. A. Popova

“…To evaluate the economic and clinical results of the aflibercept and ranibizumab angiogenesis inhibitors in the treat-and-extend regimen in patients with the “wet” form of age-related macular degeneration (wAMD). …”
Get full text

An integrated analysis of clinical and morphometric indications of atrophic forms of age-related macular degeneration by N. V. Neroeva, M. V. Ryabina, A. G. Karmokova, V. V. Neroev

“…Recently, a new classification system has been proposed, which identifies two types of atrophy in the late stage of AMD that require a more detailed study: (1) drusenassociated geographic atrophy (GA), which is the final stage of progression of dry AMD, and (2) macular atrophy (MA), which occurs in wet AMD, including the period of AMD treatment with angiogenesis inhibitors. Purpose: an integrated analysis of clinical and morphometric signs of atrophic AMD forms. …”
Get full text

Efficacy, safety and predictors of combined fruquintinib with programmed death-1 inhibitors for advanced microsatellite-stable colorectal cancer: A retrospective study by Weijie Zhang, Zhongyue Zhang, Shitong Lou, Donghui Li, Zhijun Ma, Lei Xue

“…BackgroundResearch findings have revealed that combining anti-angiogenesis inhibitors with programmed death-1(PD-1) inhibitors can reverse the immunosuppressive tumor microenvironment and enhance the antitumor immune response. …”
Get full text

Gli1-mediated tumor cell-derived bFGF promotes tumor angiogenesis and pericyte coverage in non-small cell lung cancer by Xueping Lei, Zhan Li, Manting Huang, Lijuan Huang, Yong Huang, Sha Lv, Weisong Zhang, Zhuowen Chen, Yuanyu Ke, Songpei Li, Jingfei Chen, Xiangyu Yang, Qiudi Deng, Junshan Liu, Xiyong Yu

“…Abstract Background Tumor angiogenesis inhibitors have been applied for non-small cell lung cancer (NSCLC) therapy. …”
Get full text

Sprouting Angiogenesis in Human Pituitary Adenomas by Jie Zhou, Yaomin Hu, Wende Zhu, Chuansheng Nie, Wenxiu Zhao, Alexander T. Faje, Kay E. Labelle, Brooke Swearingen, Hang Lee, E. Tessa Hedley-Whyte, Xun Zhang, Pamela S. Jones, Karen K. Miller, Anne Klibanski, Yunli Zhou, Roy J. Soberman

“…Angiogenesis in pituitary tumors is regulated mainly by PGF and VEGFC, not VEGFA and VEGFB. Angiogenesis inhibitors, such as the VEGFR2 inhibitor cabozantinib, may merit further investigation as therapies for aggressive human pituitary tumors.…”
Get full text

The efficacies and biomarker investigations of anti-programmed death-1 (anti-PD-1)-based therapies for metastatic bone and soft tissue sarcoma by Jia Lu, Ting Li, Zhichao Liao, Hui Yu, Yongtian Zhao, Haixiao Wu, Zhiwu Ren, Jun Zhao, Ruwei Xing, Sheng Teng, Yun Yang, Xiangchun Li, Kexin Chen, Jonathan Trent, Jilong Yang

“…These patients mainly received angiogenesis inhibitors combined with anti-PD-1 therapy after they became resistant to traditional treatments. …”
Get full text

The distance between new and previous incisions does not affect skin necrosis in total knee arthroplasty: a parallel-randomized controlled clinical trial by Ali Yeganeh, Mehdi Moghtadaei, Alireza Ghaznavi, Nader Tavakoli, Mohammad Soleimani, Sahand Cheraghiloohesara, Nima Taheri

“…The exclusion criteria were diabetes mellitus, hypertension, morbid obesity, smoking, vascular disorders, cardiopulmonary disorders, immune deficiencies, dementia, and taking steroids and angiogenesis inhibitors. TKA was performed through an anterior midline incision, regardless of the location of the previous scar in the intervention group. …”
Get full text

Murine breast cancer feed arteries are thin-walled with reduced α1A-adrenoceptor expression and attenuated sympathetic vasocontraction by Anne Sofie Froelunde, Marit Ohlenbusch, Kristoffer B. Hansen, Nicolai Jessen, Sukhan Kim, Ebbe Boedtkjer

“…Abstract Background Perfusion of breast cancer tissue limits oxygen availability and metabolism but angiogenesis inhibitors have hitherto been unsuccessful for breast cancer therapy. …”
Get full text

Effectiveness and safety of the bevacizumab and erlotinib combination versus erlotinib alone in EGFR mutant metastatic non-small-cell lung cancer: systematic review and meta-analys... by Rodrigo Motta-Guerrero, Alejandro Leon Garrido-Lecca, Virgilio E. Failoc-Rojas, Virgilio E. Failoc-Rojas, Ana Calle-Villavicencio, Robert Villacorta-Carranza, Yesenia Huerta-Collado, Alicia Torres-Mera, Mario J. Valladares-Garrido, Víctor Rivera-Francia, Carlos Carracedo, Luis Raez

“…However, the combination of angiogenesis inhibitors and TKI has produced discordant results. …”
Get full text

Tips and Tricks and Clinical Outcome of Cryopreserved Human Amniotic Membrane Application for the Management of Medication-Related Osteonecrosis of the Jaw (MRONJ): A Pilot Study by Stéphane Odet, Christophe Meyer, Christophe Meyer, Camille Gaudet, Elise Weber, Julie Quenot, Stéphane Derruau, Stéphane Derruau, Sebastien Laurence, Sebastien Laurence, Lisa Bompy, Marine Girodon, Brice Chatelain, Cédric Mauprivez, Cédric Mauprivez, Cédric Mauprivez, Esteban Brenet, Halima Kerdjoudj, Halima Kerdjoudj, Narcisse Zwetyenga, Philippe Marchetti, Philippe Marchetti, Anne-Sophie Hatzfeld, Anne-Sophie Hatzfeld, David Toubeau, Fabienne Pouthier, Fabienne Pouthier, Xavier Lafarge, Xavier Lafarge, Heinz Redl, Heinz Redl, Mathilde Fenelon, Mathilde Fenelon, Jean-Christophe Fricain, Jean-Christophe Fricain, Roberta Di Pietro, Roberta Di Pietro, Charlotte Ledouble, Charlotte Ledouble, Charlotte Ledouble, Thomas Gualdi, Anne-Laure Parmentier, Aurélien Louvrier, Aurélien Louvrier, Florelle Gindraux, Florelle Gindraux

“…Medication-related osteonecrosis of the jaw (MRONJ) is a complication of certain pharmacological treatments such as bisphosphonates, denosumab, and angiogenesis inhibitors. There are currently no guidelines on its management, particularly in advanced stages. …”
Get full text

Results of the use of ramucirumab in combination with irinotecan and fluoropyrimidines in the second-line chemotherapy for disseminated gastric cancer by N. S. Besova, T. A. Titova, D. L. Stroyakovsky, E. V. Perminova, S. G. Bagrova, E. S. Obarevich, V. A. Gorbunova, E. V. Artamonova, I. S. Stilidi

“…Irinotecan with fluoropyrimidines is own of the second line chemotherapy options for these patients. As angiogenesis inhibitors can enhance the efficacy of chemotherapy, we investigated the combination of irinotecan and fluoropyrimidines with ramucirumab in metastatic GC.Methods: Eligible patients had advanced morphologically verified GC and disease progression during or within 4 months following first-line therapy. …”
Get full text

Bevacizumab for the treatment of nonsquamous non-small-cell lung cancer in Portugal: a retrospective, multicenter study by Estevinho F, Soares M, Azevedo I, Queiroga H, Parente B, Brito U, Teixeira E, Sotto-Mayor R, Araújo A

“…Collaboration between the different Portuguese centers is crucial for this kind of study.Keywords: lung neoplasms, carcinoma, non-small-cell lung, nonsquamous, bevacizumab, angiogenesis inhibitors …”
Get full text

Does the use of targeted agents in advanced gastroesophageal cancer increase complete response? A meta-analysis of 18 randomized controlled trials by Pang Y, Shen Z, Sun J, Wang W

“…Subgroup analysis according to treatment TAs showed that the addition of antiepidermal growth factor receptor (EGFR) agents to chemotherapy in GEC significantly improved the CR rate in comparison with control (Peto OR 1.77; 95% CI, 1.02–3.09; P=0.044), but not for other molecular TAs (P=0.49 for angiogenesis inhibitors, P=0.66 for mesenchymal-epithelial transition inhibitors). …”
Get full text

Ontological analyses reveal clinically-significant clear cell renal cell carcinoma subtypes with convergent evolutionary trajectories into an aggressive typeResearch in context by Qi Cai, Alana Christie, Satwik Rajaram, Qinbo Zhou, Ellen Araj, Suneetha Chintalapati, Jeffrey Cadeddu, Vitaly Margulis, Ivan Pedrosa, Dinesh Rakheja, Renee M. McKay, James Brugarolas, Payal Kapur

“…Keywords: ccRCC, Morphologic heterogeneity, Prognosis, Tumor evolution, Angiogenesis inhibitors, TKIs, Immune checkpoint inhibitors…”
Get full text

Comparison of the efficacy and safety of first-line treatments for of advanced EGFR mutation-positive non-small-cell lung cancer in Asian populations: a systematic review and netwo... by Wei Chen, Julian Miao, Ying Wang, Wenzhong Xing, Xiumei Xu, Rui Wu

“…Treatment regimens involved in the included studies included first, second, and third-generation tyrosine kinase inhibitors (TKIs), TKIs plus chemotherapy, TKIs plus angiogenesis inhibitors, and platinum-containing doublet chemotherapy with or without bevacizumab. …”
Get full text

The Treatment Status of Patients in NSCLC With RET Fusion Under the Prelude of Selective RET-TKI Application in China: A Multicenter Retrospective Research by Yan Meng, Yilin Yang, Yujia Fang, Xinqing Lin, Xiaohong Xie, Haiyi Deng, Jianhui Wu, Maolin Zhou, Ni Sun, Zhanhong Xie, Ming Liu, Ming Ouyang, Yinyin Qin, Chunxia Su, Chengzhi Zhou

“…For patients having chemotherapy with or without angiogenesis inhibitors, the mPFS was 12.0 (95% CI: 11.05–13.02) months and 9.1 (95% CI: 8.31–9.89) months (p = 0.468). …”
Get full text